Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

DNAJB1-PRKACA fusion kinase peptide vaccine

A cancer peptide vaccine composed of a fusion peptide derived from the fusion protein DnaJ homolog subfamily B member 1-cAMP-dependent protein kinase catalytic subunit alpha fusion protein A (DNAJB1-PRKACA) that is encoded by the DNAJB1/PRKACA fusion gene, with potential immunomodulating and antineoplastic activities. Upon administration, the DNAJB1-PRKACA fusion kinase peptide vaccine may induce CD8 T cell- and CD4 T cell-mediated immune response against tumor cells expressing the DNAJB1-PRKACA fusion protein, which may result in the inhibition of proliferation in these tumor cells. The DNAJB1-PRKACA fusion protein is expressed in all fibrolamellar carcinoma (FLC) tumors and plays a key role in FLC tumorigenesis.
Synonym:DNAJB1-PRKACA fusion peptide vaccine
DNAJB1-PRKACA peptide vaccine
fibrolamellar hepatocellular cancer peptide vaccine
FLC peptide vaccine
Search NCI's Drug Dictionary